Publications by authors named "F Urbina"

The development of new drugs addressing serious mental health and other disorders should avoid the psychedelic experience. Analogs of psychedelic drugs can have clinical utility and are termed "psychoplastogens". These represent promising candidates for treating opioid use disorder to reduce drug dependence, with rarely reported serious adverse effects.

View Article and Find Full Text PDF

Computational approaches are widely applied in drug discovery to explore properties related to bioactivity, physiochemistry, and toxicology. Over at least the last 20 years, the exploitation of machine learning on molecular data sets has been used to understand the structure-activity relationships that exist between biomolecules and druggable targets. More recently, these methods have also seen application for phenotypic screening data for neglected diseases such as tuberculosis and malaria.

View Article and Find Full Text PDF
Article Synopsis
  • Recent advancements in machine learning, particularly with architectures like transformers and few-shot learning models, have improved text generation and image analysis tasks.
  • The 'no-free lunch' theorem indicates that there's no one-size-fits-all model; different algorithms excel in varying circumstances based on dataset characteristics.
  • The study identifies a "goldilocks zone" for model performance: few-shot learning models excel with very small datasets, transformers perform well with small-to-medium and diverse datasets, while classical models are best with larger, sufficiently sized datasets.
View Article and Find Full Text PDF

Chagas disease is caused by the single-flagellated protozoan , which affects several million people worldwide. Understanding the signal transduction pathways involved in this parasite's growth, adaptation, and differentiation is crucial. Understanding the basic mechanisms of signal transduction in could help to develop new drugs to treat the disease caused by these protozoa.

View Article and Find Full Text PDF

Butyrylcholinesterase (BChE) is a target of interest in late-stage Alzheimer's Disease (AD) where selective BChE inhibitors (BIs) may offer symptomatic treatment without the harsh side effects of acetylcholinesterase (AChE) inhibitors. In this study, we explore multiple machine learning strategies to identify BIs , optimizing for precision over all other metrics. We compare state-of-the-art supervised contrastive learning (CL) with deep learning (DL) and Random Forest (RF) machine learning, across single and sequential modeling configurations, to identify the best models for BChE selectivity.

View Article and Find Full Text PDF